Navigation Links
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:10/31/2008

t. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (File No. 333-145638), Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.

BCRXW

BIOCRYST PHARMACEUTICALS, INC.

FINANCIAL SUMMARY

Statements of Operations (Unaudited)

(in thousands, except per share)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenues:

Collaborative and other

research and development $8,894 $20,463 $22,321 $43,066

Expenses:

Research and development 15,996 29,730 51,267 64,938

General and administrative 2,471 2,595 8,023 6,980

Total expenses 18,467 32,325 59,290 71,918

Loss from operations (9,573) (11,862) (36,969) (28,852)

Interest and other income 578 878 2,167 2,080

Net loss $(8,995) $(10,984) $(34,802) $(26,772)

Basic and diluted net

loss per common share $(0.24) $(0.32) $(0.91) $(0.86)

Weighted average shares

outstanding 38,095 34,277 38,040 31,024

Balance Sheet Data (in thousands)

September 30, December 31,

2008 2007


'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
2. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
3. BioCryst to Present at the JMP Healthcare Focus Conference
4. BioCryst to Present at UBS 2008 Global Life Sciences Conference
5. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
9. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
10. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
11. BioCryst to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 According to a new ... Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract ... Trial), by End Users - Global Forecast to 2020", ... reach USD 2,107.99 million by 2020 from USD 1,034.93 ... Browse more than 75 ...
(Date:7/30/2015)... the globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s online ... contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... in Dallas, TX , ISN has additional offices in Calgary ...
(Date:7/30/2015)... New York, NY (PRWEB) , ... July 30, 2015 , ... As part of its ... raw material and technical service business units, Whitehouse Laboratories is pleased ... facility will be adjacent to the Container Center of Excellence and will be strictly dedicated ...
(Date:7/29/2015)... BANGALORE , July 30, 2015 ... Cell Market - Growth, Trends & Forecasts (2015-2020), , published ... worth US$ 30.25 billion by the end of 2020, with ... globally accounting for more than 40% of the global market ... grow at a CAGR of 13.7% during the period of ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3
... Ltd, a cancer therapeutics,company, today announced the completion ... Bio*One Capital and new investor Aravis Venture.,Additional new ... by,Adamant Biomedical Investments AG and Zurcher Kantonalbank (ZKB). ... development efforts of its,two lead compounds, SB939, a ...
... 19 /Xinhua-PRNewswire-FirstCall/ --,Pharmaceutical company Pharmaxis (ASX: PXS; ... approval to market Aridol from the Swiss ... for measuring airway hyperresponsiveness and within,Europe is ... Finland, France, Germany,Greece, Ireland, The Netherlands, Norway, ...
... the launch of the Mattel UCLA NanoPediatrics Program, ... for children, including the opportunities and risks involved. ... dedicated solely to nanomedicine and pediatric patients. ... Because children are not small adults," said Dr. ...
Cached Biology Technology:S*BIO Completes US$26 Million Equity Financing 2S*BIO Completes US$26 Million Equity Financing 3S*BIO Completes US$26 Million Equity Financing 4Pharmaxis Aridol Approved for Sale in Switzerland 2Mattel Children's Hospital UCLA launches program in nanopediatrics 2
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... July 30, 2015 after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:7/8/2015)... , N.J. and NEW YORK , July ... Guidepoint today announced BD & Guidepoint ... companies with free access to Guidepoint,s expert network services. ... that are developing cutting-edge technologies to improve healthcare delivery ... Guidepoint research manager, each start-up entrepreneur will be able ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... evidence that a direct interaction between vitamin D and ... multiple sclerosis (MS). The research, published on 6 February ... that vitamin D deficiency during pregnancy and the early ... MS later in life. MS is the most ...
... (NYSE: CSC ) announced today that it ... and Support Services Unrestricted contract by the Department of ... (IDIQ) contract covers a broad range of services, solutions ... BTF business and program units. The contract has a ...
... Feb. 3 SectorWatch.biz announces the availability of a commentary ... Controls, Inc. (OTC Bulletin Board: FOUR), Magal Security Systems Ltd. ... NSSC ), Pointer Telocation (Nasdaq: PNTR ... Systems Inc. (NYSE: CKP ).To view the FiSpace.net ...
Cached Biology News:Genetic study shows direct link between vitamin D and MS susceptibility 'gene' 2Genetic study shows direct link between vitamin D and MS susceptibility 'gene' 3CSC Awarded Department of Defense Biometrics Contract 2SectorWatch.biz Issues Commentary for Investors of Homeland Defense Companies FOUR, MAGS, NSSC, PNTR, BCO, and CKP 2